[1] 胡朝军,李永哲. 重视自身免疫性肝病相关自身抗体的规范检测与合理应用. 中华检验医学杂志,2014,37(2):81-83. [2] Miyake Y,Yamamoto K,Matsushita H,et al.Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis. Hepatol Res,2015,44(13):1299-1307. [3] Oba J,Nakahara T,Abe T,et al.Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival. J Am Acad Dermatol,2014,70(5):954-956. [4] Dirks J,Egli A,Sester U,et al.Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells. Transpl Infect Dis,2013,15(1):79. [5] Ye HO,Adams DH.Regulatory T cells and autoimmune hepatitis:defective cells or a hostile environment. J Hepatol,2012,57(1):6-8. [6] Grant CR,Liberal R,Holder BS,et al.Dysfunctional CD39 POS,regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology,2014,59(3):1007-1015. [7] Jiang L,Wang L,Li PF,et al.Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. Onco Targets Ther,2015,8(2):1451. [8] Grzywnowicz M,Karczmarczyk A,Skorka K,et al.Expression of programmed death 1 ligand in different compartments of chronic lymphocytic leukemia. Acta Haematol,2015,134(4):255-262. [9] Solaymani-Mohammadi S,Lakhdari O,Minev I,et al.Lack of the programmed death-1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules. J Leukoc Biol,2016,99(3):475-482. [10] 董荣乔,周东方,韩冉,等. 干扰素α对慢性丙型肝炎患者外周血T淋巴细胞表面程序性死亡受体-1表达的影响. 中华肝脏病杂志,2013,21(12):899-902. [11] 邵鸣,肖玉珍. 自身免疫性肝炎Ⅱ型1例. 实用肝脏病杂志,2010,13(5):250-250. [12] 刘泽,蔡少平. 中晚期自身免疫性肝炎-原发性胆汁性肝硬化重叠综合征的临床病理研究. 实用肝脏病杂志,2008,10(1):18-19. [13] Kremmler L,Blank CU.The clinical relevance of the programmed death-1(PD-1) receptor. Inter Praxis,2014,54(4):775-787. [14] Alaghehbandan R,Stehlik J,Trpkov K,et al.Programmed death-1(PD-1) receptor/PD-1 ligand(PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. Ann Diagn Pathol, 2017,29:17. [15] Muenst S,Schaerli AR,Gao F,et al.Expression of programmed death ligand 1(PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat,2014,146(1):15-24. [16] Ishii H,Azuma K,Kawahara A,et al.Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol, 2015,10(3):426-430. [17] Seki T,Kiyosawa K,Inoko H,et al.Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology,2010,12(6):1300-1304. [18] Richardson PD,James PD,Ryder SD.Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol,2000,33(3):371-375. [19] Kearl TJ,Jing W,Gershan JA,et al.Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol,2013,190(11):5620-5628. [20] Cao D,Xu H,Guo G,et al.Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure. Inflammation,2013,36(1):110-120. [21] Shao R,Fang Y,Yu H,et al.Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients:a prospective cohort study. Crit Care,2016,20(1):124. |